NMPA conditionally approves COVID-19 vaccine developed by Sinopharm's Wuhan institute
The National Medical Products Administration (NMPA) conditionally approved the registration application of the inactivated COVID-19 vaccine (Vero cell) developed by the Wuhan Institute of Biological Products administered by Sinopharm on Feb 25. The vaccine is suitable for the prevention of COVID-19 caused by the novel coronavirus.
In accordance with the provisions of the Vaccine Administration Law and the Drug Administration Law and based on the requirements of the special drug approval procedures, the NMPA conducted emergency review and granted conditional market approval to the vaccine. The marketing authorization holder of the vaccine is required to continue relevant research, fulfill conditional requirements and submit the results of subsequent research in a timely manner.